Megumi Morimoto

A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells

Yoshinori Ishikawa, Kanae Gamo, Masato Yabuki et al. · Molecular Cancer Therapeutics · 2016 · 105 citations

Medicine, Molecular Biology, Oncology +13

Intratumor Heterogeneity in Primary Kidney Cancer Revealed by Metabolic Profiling of Multiple Spatially Separated Samples within Tumors

Takatsugu Okegawa, Megumi Morimoto, Satoru Nishizawa et al. · EBioMedicine · 2017 · 68 citations · Full text

Medicine, Cancer Biology, Oncology +17

Usefulness of Endobronchial Ultrasonography With a Guide Sheath and Virtual Bronchoscopic Navigation for Ground-Glass Opacity Lesions

Yasuyuki Ikezawa, Naofumi Shinagawa, Noriaki Sukoh et al. · The Annals of Thoracic Surgery · 2016 · 58 citations · Full text

Veterinary Medicine, Radiology, Diagnostic Imaging +16

Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs) Part III: Discovery of 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2f as a clinical candidate

Katsuji Aikawa, Moriteru Asano, Koji Ono et al. · Bioorganic & Medicinal Chemistry · 2017 · 40 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication

Yoshinori Ishikawa, K. Nakayama, Megumi Morimoto et al. · Oncogenesis · 2017 · 38 citations · Full text

Medicine, Molecular Biology, Oncology +16